Abstract:BACKGROUND:Human myelogenous leukemia characterized by either the non random t(8; 21)(q22; q22) or t(16; 21)(q24; q22) chromosome translocations differ for both their biological and clinical features. Some of these features could be consequent to differential epigenetic transcriptional deregulation at AML1 targets imposed by AML1-MTG8 and AML1-MTG16, the fusion proteins deriving from the two translocations. Preliminary findings showing that these fusion proteins lead to transcriptional downregulation of AML1 targets, marked by repressive chromatin changes, would support this hypothesis. Here we show that combining conventional global gene expression arrays with the power of bioinformatic genomic survey of AML1-consensus sequences is an effective strategy to identify AML1 targets whose transcription is epigenetically downregulated by the leukemia-associated AML1-MTG16 protein. RESULTS:We interrogated mouse gene expression microarrays with probes generated either from 32D cells infected with a retroviral vector carrying AML1-MTG16 and unable of granulocyte differentiation and proliferation in response to the granulocyte colony stimulating factor (G-CSF), or from 32D cells infected with the cognate empty vector. From the analysis of differential gene expression alone (using as criteria a p value < 0.01 and an absolute fold change > 3), we were unable to conclude which of the 37 genes downregulated by AML1-MTG16 were, or not, direct AML1 targets. However, when we applied a bioinformatic approach to search for AML1-consensus sequences in the 10 Kb around the gene transcription start sites, we closed on 17 potential direct AML1 targets. By focusing on the most significantly downregulated genes, we found that both the AML1-consensus and the transcription start site chromatin regions were significantly marked by aberrant repressive histone tail changes. Further, the promoter of one of these genes, containing a CpG island, was aberrantly methylated. CONCLUSION:This study shows that a leukemia-associated fusion protein can impose a distinct epigenetic repressive signature at specific sites in the genome. These findings strengthen the conclusion that leukemia-specific oncoproteins can induce non-random epigenetic changes.

Epigenetic modifications in hematopoietic ecosystem: a key tuner from homeostasis to acute myeloid leukemia

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

Reprogramming of RNA m6A Modification Is Required for Acute Myeloid Leukemia Development

Internal m6A and m7G RNA modifications in hematopoietic system and acute myeloid leukemia

N6-methyladenosine RNA Modifications: a Potential Therapeutic Target for AML

Epigenetic Regulation in Hematopoiesis and Its Implications in the Targeted Therapy of Hematologic Malignancies

Physio-pathological Effects of N6-methyladenosine and Its Therapeutic Implications in Leukemia

Epigenetic Abnormalities in Acute Myeloid Leukemia and Leukemia Stem Cells.

Characterization of m6A regulator‐mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia

One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia

Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia

RNA m<SUP>6</SUP>A modification: Mapping methods, roles, and mechanisms in acute myeloid leukemia

Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options

m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia

The epigenetic state of the cell of origin defines mechanisms of leukemogenesis

Dna Methyltransferases in Hematologic Malignancies

The Progress of Epigenetic Modification in Hematological Malignancies Research

Epigenetic Modifications in Acute Myeloid Leukemia: the Emerging Role of Circular RNAs (Review).

Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity